GlaxoSmithKline's HIV drug Cabenuva scores FDA nod for 2-month dosing
Last January, when GlaxoSmithKline’s ViiV Healthcare won a long-awaited approval for its long-acting HIV treatment Cabenuva, it was hailed as a game-changer as it removed the burden of taking a daily pill.
Last January, when GlaxoSmithKline’s ViiV Healthcare won a long-awaited approval for its long-acting HIV treatment Cabenuva, it was hailed as a game-changer as it removed the burden of taking a daily pill.
Just over a year later, another nod from the FDA has made Cabenuva an even more convenient option, allowing a boosted formulation of the injected treatment to be taken every two months, instead of monthly.
The drug is for virologically suppressed adults on a stable regimen with no history of treatment failure and no known or suspected resistance to the two agents that make up Cabenuva—ViiV’s cabotegravir and Johnson & Johnson’s Edurant.
“We know some people living with HIV struggle with taking daily oral pills and Cabenuva may allow them to maintain viral suppression while significantly reducing dosing to as few as six times a year,” Lynn Baxter, ViiV’s chief in North America, said in a release.